American Association for Cancer Research (AACR) 2024
The AACR recently held its 2024 conference from April 5-10, 2024. Click the links below to learn about MBC-related reports from this meeting.
A New Type of PARP Inhibitor for Some People with HER2-Negative MBC
- Cancer Therapy Advisor: A new type of PARP inhibitor called saruparib is safe and effective for some people with HER2-negative MBC
- American Association for Cancer Research: A new type of PARP inhibitor called saruparib is safe and effective for some people with HER2-negative MBC
Understanding Resistance to Antibody-Drug Conjugates (ADCs) for MBC
- Massachusetts General Hospital: Mutations in a gene called TOP1 may lead to resistance to some ADCs and suggest new ways to overcome resistance (scroll to “TOP1 mutations mediate cross resistance to ADCs in metastatic breast cancer”)